search
Back to results

Comparison of Five Treatments in Patients With Plantar Warts (VRAIE)

Primary Purpose

Plantar Warts

Status
Terminated
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Salicylate ointment
Imiquimod
5-Fluoro-Uracil
Cryotherapy
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Plantar Warts focused on measuring Occlusive dressings, Salicylate ointment, Cryotherapy, Topical 5-fluoro-uracil, Imiquimod, Randomized clinical trial, Plantar warts

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patient aged 18 years or more.
  • Clinical evaluation
  • Number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10 cm, whether previously treated or not
  • In treated patients, all potentially active treatment on warts since at least one month should be stopped.
  • Effective contraception for women of childbearing age
  • Immunocompetent patients
  • Patient with one or more warts on soles and board feet.

    • MYRMECIE : rounded warts, deep, covered with a stratum corneum more or less thick; after stripping, appear black points, very specific; often painful to pressure. They are lonely, single or not. They could regroup galley thick. The stripping can them to individualize.
    • Mosaic : plate small warts, superficial, often sitting on the heel or Forefoot. Little painful, they are often ignored by the patients when they appear
  • Patient affiliated to the French social security.

Exclusion Criteria:

  • Patient suspected to be immunocompromised
  • Patient aged under 18 years
  • Patient refusing to sign the consent
  • Pregnant or lactating women
  • Plantar calluses
  • Known hypersensitivity to imiquimod (Aldara®) or any excipients of the cream (isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl hydroxybenzoate, propyl hydroxybenzoate, xanthan gum, purified water)
  • Known hypersensitivity to 5 fluoro-uracil (Efudix®) or any excipients of gel (stearyl alcohol, Vaseline, polysorbate 60, propyleneglycol, purified water - conservatives: METHYL PARAHYDROXYBENZOATE, PROPYL PARAHYDROXYBENZOATE)
  • Contra-indication to Pomade M.O Cochon® (Known allergy to any components)
  • Known hypersensitivity to Blenderm®
  • Extra plantar concomitant warts (to exclude risk of endogenous recontamination by an extra plantar site)
  • Plantar hyperhidrosis making impossible adhesion of plaster.

Sites / Locations

  • Medical center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Salicylate ointment

Imiquimod

5-fluoro-uracil

Cryotherapy

Arm Description

Salicylate ointment under occlusion (pomade M.O Cochon®)

Imiquimod : Aldara®

5-fluoro-uracil cream : Efudix®

liquid nitrogen : Cryotherapy

Outcomes

Primary Outcome Measures

Complete clinical remission of the warts assessed by the dermatologist

Secondary Outcome Measures

Time remission
Number of warts in remission vs baseline
Time to first relapse
Percentage of relapse (phone call assessment)
Safety
Evaluation of distress (visual analogic scale)
Compliance.

Full Information

First Posted
November 30, 2009
Last Updated
January 10, 2017
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Society of Dermatology and venerology
search

1. Study Identification

Unique Protocol Identification Number
NCT01059110
Brief Title
Comparison of Five Treatments in Patients With Plantar Warts
Acronym
VRAIE
Official Title
Comparison of Occlusive Dressings, Salicylate Ointment, Cryotherapy, Topical 5-fluoro-uracil and Imiquimod in Immunocompetent Patients Presenting Plantar Warts in Office-based Settings: a Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Terminated
Why Stopped
Difficulty to enrollment patients
Study Start Date
February 2010 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
December 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Society of Dermatology and venerology

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The principal objective of the study is to compare 5 usual strategies in the management of plantar warts which did not cure after 5 weeks of a salicylate ointment given just prior the trial. The trial will include immunocompetent patients coming from the community and should help the office-based dermatologists and hospital in the decision-making therapeutic process.
Detailed Description
Four and a half million individuals in France have warts (SOFRES poll 2002). Notably, plantar warts are considered to be the most common reason for consulting a private practitioner, despite the absence of robust epidemiological data. Although benign, plantar warts are associated with a certain degree of morbidity: pain, difficulty walking, and intra- and interindividual contagion. Despite the frequency of plantar warts and patients high expectations for their treatments, which are numerous for immunocompetent patients, those remedies have only been evaluated in undeniably inadequate ways. Patient demand for therapy is strong, with those affected going from one physician to another, in the search for the "good treatment". For all the reasons evoked in the context of skin diseases, healing warts can indeed represent a public health objective. One of the difficulties of evaluating treatments is the frequency of spontaneous complete remissions (natural history) and/or under placebo, assessed at 30% [range: 0-73%] in a short-term trial (10 weeks). In addition, professionals experiences support frequent relapses that have been very poorly evaluated in therapeutic trials. Keratolytic treatment, usually salicylated petroleum jelly, is the standard therapy according to the Cochrane Review. In practice, this therapy usually combines manual shaving, done by the patient him/herself or the physician. Supplementing this basic therapy with a physical (standard cryotherapy), chemical (5-fluorouracil; Efudix®) or immunological adjunct (imiquimod; Aldara®), to achieve the desired effect of increasing the frequency and/or rapidity of complete cure, has never been examined in a large randomized-controlled trial. A population comprised of patients with warts still "resistant" after 5 weeks of keratolytic therapy with 50% salicylic acid (PommadeM.O Cochon®) followed by a 1-week washout was deliberately retained because it is this precise setting that poses therapeutic difficulties in routine practice. The 1-week washout will allow the skin to heal a little and facilitate the diagnosis of failures; and, moreover, the strategy of pretreatment with scraping would not be unduly weakened.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Plantar Warts
Keywords
Occlusive dressings, Salicylate ointment, Cryotherapy, Topical 5-fluoro-uracil, Imiquimod, Randomized clinical trial, Plantar warts

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
358 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Salicylate ointment
Arm Type
Experimental
Arm Description
Salicylate ointment under occlusion (pomade M.O Cochon®)
Arm Title
Imiquimod
Arm Type
Experimental
Arm Description
Imiquimod : Aldara®
Arm Title
5-fluoro-uracil
Arm Type
Experimental
Arm Description
5-fluoro-uracil cream : Efudix®
Arm Title
Cryotherapy
Arm Type
Experimental
Arm Description
liquid nitrogen : Cryotherapy
Intervention Type
Drug
Intervention Name(s)
Salicylate ointment
Other Intervention Name(s)
pommade M.O Cochon®
Intervention Description
cream, one application every night, for 90 days
Intervention Type
Drug
Intervention Name(s)
Imiquimod
Other Intervention Name(s)
Aldara® 5%
Intervention Description
cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
Intervention Type
Drug
Intervention Name(s)
5-Fluoro-Uracil
Other Intervention Name(s)
Efudix® 5%
Intervention Description
cream, one application every night, during 12 hours, for 90 days
Intervention Type
Drug
Intervention Name(s)
Cryotherapy
Other Intervention Name(s)
Liquid nitrogen
Intervention Description
2 cycles of 5 seconds after obtention of halo of white
Primary Outcome Measure Information:
Title
Complete clinical remission of the warts assessed by the dermatologist
Time Frame
at 90 days
Secondary Outcome Measure Information:
Title
Time remission
Time Frame
at 30, 60 and 90 days
Title
Number of warts in remission vs baseline
Time Frame
at 30, 60 and 90 days
Title
Time to first relapse
Time Frame
at 30, 60, 90, 120, 180, 360 and 720 days
Title
Percentage of relapse (phone call assessment)
Time Frame
at 360 days and 720 days
Title
Safety
Time Frame
at 90 days
Title
Evaluation of distress (visual analogic scale)
Time Frame
at 90 days
Title
Compliance.
Time Frame
at 90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patient aged 18 years or more. Clinical evaluation Number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10 cm, whether previously treated or not In treated patients, all potentially active treatment on warts since at least one month should be stopped. Effective contraception for women of childbearing age Immunocompetent patients Patient with one or more warts on soles and board feet. MYRMECIE : rounded warts, deep, covered with a stratum corneum more or less thick; after stripping, appear black points, very specific; often painful to pressure. They are lonely, single or not. They could regroup galley thick. The stripping can them to individualize. Mosaic : plate small warts, superficial, often sitting on the heel or Forefoot. Little painful, they are often ignored by the patients when they appear Patient affiliated to the French social security. Exclusion Criteria: Patient suspected to be immunocompromised Patient aged under 18 years Patient refusing to sign the consent Pregnant or lactating women Plantar calluses Known hypersensitivity to imiquimod (Aldara®) or any excipients of the cream (isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl hydroxybenzoate, propyl hydroxybenzoate, xanthan gum, purified water) Known hypersensitivity to 5 fluoro-uracil (Efudix®) or any excipients of gel (stearyl alcohol, Vaseline, polysorbate 60, propyleneglycol, purified water - conservatives: METHYL PARAHYDROXYBENZOATE, PROPYL PARAHYDROXYBENZOATE) Contra-indication to Pomade M.O Cochon® (Known allergy to any components) Known hypersensitivity to Blenderm® Extra plantar concomitant warts (to exclude risk of endogenous recontamination by an extra plantar site) Plantar hyperhidrosis making impossible adhesion of plaster.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olivier CHOSIDOW, MD,PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical center
City
Athis Mons
ZIP/Postal Code
91200
Country
France

12. IPD Sharing Statement

Learn more about this trial

Comparison of Five Treatments in Patients With Plantar Warts

We'll reach out to this number within 24 hrs